#Kaiser Permanente

People who start HIV treatment early have a normal life expectancy, according to new findings.

The trial will enroll healthy volunteers to test the vaccine’s safety and ability to trigger an immune response.

But even starting antiretrovirals with a high CD4 count doesn’t close the wide gap in years lived without major health problems.

Electronic prompts for clinicians to recommend Truvada to people at risk for HIV could help increase PrEP’s impact.

A speedy overview of the major scientific findings presented at the International AIDS Conference in Amsterdam (AIDS 2018)

A new analysis broke down U.S. PrEP use by location and demographics and compared it with corresponding HIV diagnosis rates.

Courting controversy, the NIH considers a shift away from the development of new vaginal or rectal-based HIV prevention products.

Because PrEP can avert the need for expensive lifelong HIV treatment, its own considerable expense often makes good economic sense.

Not satisfied with its success, health care group Kaiser Permanente looks to address those who stop or only consider PrEP and contract HIV.

The science behind Truvada as pre-exposure prophylaxis reveals an awesome tool that is apparently already helping shrink U.S. HIV rates.

The cohort study also found that older individuals on PrEP were at greater risk of reduced kidney function.

What does the future hold for new pre-exposure prophylaxis (PrEP) against HIV, including long-acting injectables and less toxic drugs?

HIV raises the risk of heart disease. What can you do to lower that risk?

Two and a half years into a PrEP program in San Francisco, none of the more than 600 gay men taking Truvada have contracted the HIV.

The higher risk of heart attack among people living with HIV may be greatly reduced and even eliminated through HIV treatment and proper atten...

People with HIV have a 40 percent greater chance of stroke than those without the virus; however, having high CD4 cells erases this increases...